Promoter holding
64.27%
SF
Syncom Formulations (India) Limited - Due diligence report
A 360° intelligence report on Syncom Formulations: trust score, financial health, credit view, compliance, directors, growth and distress si…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Syncom Formulations — 360° Intelligence Report
Generated from MCA filings & public records44/100
Trust Score
Caution Indicated
Syncom Formulations is assessed as Caution Indicated with a Trust Score of 44/100. Syncom Formulations is an active public limited indian non-government company incorporated in 1988, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.
Report generated on 11 Jul 2026 from the latest processed filings. Syncom Formulations (India) Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreCaution Indicated
44/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
55/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
35/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
40/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
- Negative operating earnings - debt service depends on external support.
Charges position: 1 open (9.50 cr) · 19 satisfied (156.68 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Hdfc Bank Limited | 2 | 48.0 cr |
| Dena Bank | 11 | 48.0 cr |
| Industrial Developement Bank Of India | 1 | 48.0 cr |
| Industrial Development Bank Of India | 1 | 48.0 cr |
| The Saraswat Co-Operative Bank Ltd. | 3 | 48.0 cr |
| Indian Overseas Bank | 2 | 48.0 cr |
Compliance Score: 55/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: DSE, BSE, SEBI.
- Litigation present in 1 court forum(s).
- Delayed payments to MSME suppliers disclosed (25 disclosure(s)).
- 7 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 35/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RITESH KUMAR LUNKAD | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANKIT JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KEDARMAL SHANKARLAL BANKDA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIJAY SHANKARLAL BANKDA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAHUL VIJAY BANKDA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RUCHI JINDAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANKIT KEDARMAL BANKDA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VAISHALI AGRAWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RINKI ANKIT BANKDA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANKIT KEDARMAL BANKDA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rahul Vijay Bankda | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 11 directors on the board.
- ANKIT JAIN has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 5 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2025)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
3
Group entities
3
Capital events
10 allotment(s) · 16 transfer(s)
Promoters hold the largest single block of equity - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Sante Biotech Private Limited | Subsidiary Company | 74.00% |
| Synmex Pharma Private Limited | Subsidiary Company | 74.00% |
| Vincit Biotech International Private Lim | Subsidiary Company | 74.00% |
Key managerial personnel: KEDARMAL SHANKARLAL BANKDA (Whole-time director) · RAHUL VIJAY BANKDA (CFO) · ANKIT KEDARMAL BANKDA (Whole-time director) · RINKI ANKIT BANKDA (Whole-time director) · ANKIT KEDARMAL BANKDA (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 40
Growth signals & trust indicators
Operating for 38+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
Compliance score is weak (55/100).
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 34.06 Lakh.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence47/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 3 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment33/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 9.50 cr already registered.
- Compliance gaps should be priced into terms.
Investor view29/100
Limited indicators at present
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events01 Oct 2025
Charge created
Hdfc Bank Limited - 9.50 cr
08 Sep 2025
Director appointed
Rahul Vijay Bankda (Cfo)
09 Aug 2025
Director appointed
RAHUL VIJAY BANKDA (CFO)
Director appointed
ANKIT KEDARMAL BANKDA (Whole-time director)
08 Aug 2025
Director appointed
VIJAY SHANKARLAL BANKDA (Officer in default)
Director ceased
ANKIT KEDARMAL BANKDA
07 Aug 2025
Director ceased
KEDARMAL SHANKARLAL BANKDA
31 Mar 2025
Latest balance sheet
Filed with ROC
27 Mar 2025
Charge satisfied
Hdfc Bank Limited
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Share transfer (FY 2024)
10500.00000000 shares to Vijendra Kumar Jain
Share transfer (FY 2024)
3500.00000000 shares to Nilesh Manohar Rambhad
Share transfer (FY 2024)
3500.00000000 shares to Bipin Chunilal Mithani
Share transfer (FY 2024)
5000.00000000 shares to Tara Bhatt
Director ceased
VINOD KUMAR KABRA
10
Key Observations
Auto-generated from the data aboveRevenue declined 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
11 active director(s) / partner(s); review board churn before relying on management continuity.
7 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 3 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 10 security allotment(s) - amounts available in the full report.
1 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Medisys Biotech Private Limited | U24231HP2005PTC030915 | Kala Amb, Himachal Pradesh, India |
| Genesis Ibrc India Limited | L47733AP1992PLC107068 | Eluru, Andhra Pradesh, India |
| Rishab Healthcare Private Limited | U51397CH2005PTC027979 | Chandigarh, Chandigarh, India |
| Rathi Graphic Technologies Limited | L26960UP1991PLC013770 | Ghaziabad, Uttar Pradesh, India |
| Stelis Biopharma | L74140MH2007PLC432497 | Thane, Maharashtra, India |
| Norris Medicines | L24230GJ1990PLC086581 | Ankleshwar, Gujarat, India |
| Dream Green Petro-Chem Private Limited | U24296MH2014PTC252999 | Nashik, Maharashtra, India |
| Colinz Laboratories | L24200MH1986PLC041128 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Syncom Formulations before audits and certifications: compliance score 55/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Syncom Formulations: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Enhanced diligence advised. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Limited indicators at present. Growth score 40/100, margin trends, ownership structure and peer set for Syncom Formulations - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 44/100, distress signals and MSME payment-delay disclosures - know whether Syncom Formulations pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Syncom Formulations - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Syncom Formulations an active company?
Syncom Formulations has MCA status “Active” with a compliance score of 55/100 (Moderate).
Is Syncom Formulations financially healthy?
Syncom Formulations has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Syncom Formulations?
Its overall Trust Score is 44/100 (Caution Indicated). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Syncom Formulations?
Promoters hold the largest single block of equity - exact percentages are in the full report. 11 active director(s) are on record.
Does Syncom Formulations have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 19 earlier charge(s) stand satisfied.
Is Syncom Formulations up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 55/100 (Moderate).
Is it risky to lend to Syncom Formulations?
Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
